SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-023589
Filing Date
2024-03-18
Accepted
2024-03-18 17:17:00
Documents
14
Period of Report
2024-03-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0202028-8k_protara.htm   iXBRL 8-K 30546
2 SEPARATION AND CONSULTING AGREEMENT AND RELEASE, DATED AS OF MARCH 18, 2024, BY ea020202801ex10-1_protara.htm EX-10.1 59371
  Complete submission text file 0001213900-24-023589.txt   282888

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tara-20240318.xsd EX-101.SCH 3018
4 XBRL LABEL FILE tara-20240318_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tara-20240318_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0202028-8k_protara_htm.xml XML 3626
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 24760090
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)